Fostemsavir plus optimized background therapy was associated with improvements in immune biomarkers among HTE patients with MDR HIV infection.

Spread This News Despite high rates of untreated osteoporosis and previous fractures among menopausal women in Zimbabwe — ...

A 33-year-old man presented to our dermatology clinic with a 1-month history of two painless ulcers on his right arm and ...

More than 150 homeless people and military veterans received royal treatment Oct. 23 during the Lorain County Task Force for ...

Some people infected with HIV are teeming with virus, but don’t get sick. Their resistive powers probably come from a mix of ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

The Pakistan Stock Exchange (PSX) held a gong ceremony to celebrate the listing of BF Biosciences Limited (BFBIO). BFBIO is a ...

The 1) Market is expected to reach a substantial USD 34.83 billion by 2033, according to a new report. This reflects a ...

HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company pioneering CRISPR-based programmable genome medicines, today announced the appointment of Dr. TJ Cradick as Chief ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Improving HIV Treatment in Children and Adolescents -- The Right Way July 18, 2024 — Globally, around 2.6 million children and adolescents are currently living with HIV, the majority of them in ...